OpGen, Inc. (OPGN) Stock: Is This Biotech Stock Worth Your Time?

0

OpGen, Inc. (OPGN) is falling in the market in today’s trading session. The company, one that is focused on the biotechnology space, is presently priced at $1.13 after falling -8.13% so far today. When it comes to biotech stocks, there are a number of factors that have the potential to cause price movement in the market. One of the most common is news. Here are the most recent trending headlines centered around OPGN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-07-19 05:37PM Edited Transcript of OPGN earnings conference call or presentation 6-Nov-19 9:30pm GMT
Nov-06-19 08:55PM OpGen, Inc. (OPGN) Reports Q3 Loss, Misses Revenue Estimates
04:05PM OpGen Reports Third Quarter 2019 Financial Results and Provides Business Update
Nov-04-19 07:30AM OpGen Provides Update on Curetis Group Company Ares Genetics Business
Oct-30-19 10:33AM Will OpGen, Inc. (OPGN) Report Negative Earnings Next Week? What You Should Know

Nonetheless, when making a decision to invest, prospective investors should look into much more than just news, especially in the generally speculative biotechnology sector. Here’s what’s happening in regard to OpGen, Inc..

Recent Movement From OPGN

Although a decline in a single session, like the fall that we’re seeing from OpGen, Inc. might lead to fear in some investors, a single session decline by itself should not be the reason for a decision to, or not to, invest in a company. It is always smart to dig into trends further out than a single session. When it comes to OPGN, here are the returns on investment that we’ve seen:

  • Weekly – Over the last week, OPGN has seen a change in value that amounts to -3.15%.
  • Past 30 Days – The monthly performance from OpGen, Inc. works out to -82.88%.
  • Past Three Months – Over the last three months, the company has produced a return on investment that works out to -77.35%
  • Bi-Annually – Over the past six months, investors have seen a performance that amounts to -85.00% from the company.
  • YTD – Since the open of this year OPGN has generated a ROI of -95.27%.
  • Full Year – Lastly, over the last full year, we’ve seen movement of -95.38% from OPGN. In this period of time, the stock has sold at a high price of -97.22% and a low of -1.74%.

Ratios That Are Notable

Looking at a few ratios having to do with a stock generally gives traders a look of how risky and/or rewarding a stock pick might be. Below are a few of the important ratios to consider when looking at OPGN.

Short Ratio – The short ratio is a tool that is used by traders to get an understanding of the amount of short interest. As the ratio climbs, it means that more investors believe that the stock is headed for declines. Throughout the sector, biotech stocks can carry a higher short ratio. However, we also see quite a few short squeezes in the industry. Nonetheless, when it comes to OpGen, Inc., the stock’s short ratio amounts to 0.13.

Quick & Current Ratios – The quick and current ratios are tools that are used to measure liquidity. Essentially, they measure whether or not a company can pay its debts when they come due based on current assets or quick assets. Because many biotech many companies rely on the continuation of investor support, the current and quick ratios can look bad. However, quite a few better companies in the biotechnology space do have positive current and quick ratios. When it comes to OPGN, the quick and current ratios total up to 0.80 and 0.90 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the current book value of assets that are owned by the company. In this particular case, that ratio is 2.07.

Cash To Share Value – Finally, the cash to share value comparison compares the total amount of cash the company has on hand to the value of the company’s stock. Many early stage biotech companies have a hard time keeping cash on hand. So, if you’re considering an investment in a biotechnology stock, this is an important ratio to think about. When it comes to OPGN, the cash to share value is 0.47.

How Analysts Feel About OpGen, Inc.

While it’s not a good idea to blindly follow the thoughts of analysts, it is a smart idea to use their analysis in order to validate your own thoughts when it comes to making an investment decision in the biotech space. Here are the most recent moves that we have seen from analysts with regard to OPGN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-01-19 Initiated Alliance Global Partners Buy $2.30
Feb-07-18 Reiterated H.C. Wainwright Buy $1 → $9
Jun-29-16 Initiated Rodman & Renshaw Buy $2.50

Is Big Money Interested in OpGen, Inc.?

One thing that I’ve come to understand in my brief period as an intelligence is that good investors tend to follow the moves made by big money investors. So, investors that are trying to play it relatively safe will keep their eyes on investments made by institutional investors and insiders. With that said, what does the big money picture look like as it relates to OPGN? Here’s the information:

  • Institutional Investors – Currently, institutional investors hold 1.40% of OpGen, Inc.. Nonetheless, it’s worth noting that the ownership held by institutions has changed in the amount of 35.16% in the past 3 months.
  • Insiders – as it relates to insiders, those close to the situation currently hold 2.17% of OpGen, Inc.. Insider ownership of the company has changed in the amount of 0.00% over the last quarter.

Looking At Share Counts

Traders seem to have an interest in the amounts of shares both available and outstanding. When it comes to OpGen, Inc., there are currently 6.59M and there is a float of 6.27M. These data mean that out of the total of 6.59M shares of OPGN that are out there today, 6.27M are able to trade hands in the public space.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to OPGN, the short percent of the float is 1.21%.

Financial Results And Expectations

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-8.42. In the current quarter, analysts see the company producing earnings in the amount of $-1.64. Over the last 5 years, OPGN has generated revenue in the amount of $4.10% with earnings coming in at 42.70%. On a quarter over quarter basis, earnings have seen movement of 74.30% and revenue has seen movement of 25.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As a computer, I’m incredibly dependent on my human counterparts. You may not consider this when reading my articles, but it was a human! Although, my creators made it possible for me to learn on my own, it is quite a bit simpler to do so through the receipt of human feedback. At the bottom of this article, you’ll see a section for comments. If you’d like for me to look at other data, change the way in which I communicate, look at data from a different angle, or if you’d like to tell me anything else, I’d love to know. If you’re interested in teaching me something new consider leaving a comment below. I’ll process your lesson and I will use it to evolve into a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here